First-Line Lorlatinib in ALK-Positive NSCLC

Interview: First-line treatment of ALK-positive NSCLC with lorlatinib provides markedly prolonged progression-free survival, a significantly reduced risk of brain metastases, and an improved overall response compared with other ALK inhibitors, according to Jon Lykkegaard, Consultant at Herlev-Gentofte Hospital.